account_balance
Investment manager · 13F filer · SEC CIK 1910264
SR One Capital Management, LP
Reported value$1.04Bas of Jun 30, 2026
Positions15 3 new, 2 sold out
Top 10 weight95.1%MANE alone is 28%
FiledAug 1243 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
MANEVeradermics, Inc.
28.4%
ZBIOZenas BioPharma, Inc
12.3%
CRSPCrispr Therapeutics AG
10.7%
AVLNAvalyn Pharma, Inc
10.5%New
DSGNDesign Therapeutics, Inc.
9.1%
ODTXOdyssey Therapeutics, Inc.
6.8%New
ALMSAlumis Inc.
5.3%
ORICORIC Pharmaceuticals, Inc.
4.8%Added +2%
MLYSMineralys Therapeutics Inc.
4.1%
SPRYARS Pharmaceuticals, Inc.
3.1%
MOBI2.6%NKTXMANEVeradermics, Inc.
28.4%
ZBIO12.3%CRSP10.7%AVLN10.5%DSGN9.1%ODTX6.8%ALMS5.3%ORIC4.8%MLYS4.1%SPRYMOBI2.6%NKTXBoxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
MANE Veradermics, Inc. 28.4% HeldZBIO Zenas BioPharma, Inc 12.3% HeldCRSP Crispr Therapeutics AG 10.7% HeldAVLN Avalyn Pharma, Inc 10.5% NewDSGN Design Therapeutics, Inc. 9.1% HeldODTX Odyssey Therapeutics, Inc. 6.8% NewALMS Alumis Inc. 5.3% HeldORIC ORIC Pharmaceuticals, Inc. 4.8% Added +2%MLYS Mineralys Therapeutics Inc. 4.1% HeldSPRY ARS Pharmaceuticals, Inc. 3.1% HeldMOBI Mobia Medical, Inc 2.6% NewNKTX Nkarta, Inc. 0.9% Held
What changed